PMC

9q31.2-rs865686 and breast cancer risk amongst women of European ancestry stratifying by ER, PR, and HER2 receptor status*. Ca, no. cases; Co, no. controls; * P for heterogeneity (P_het) in the OR by ER status: 6.9 × 10^–4 amongst PR^– tumors and 0.52 amongst PR⁺ tumors. P_het in the OR by PR status: 0.13 amongst ER^– cases and 0.52 amongst ER⁺ cases.

Forest plot of the association of 9q31.2-rs865686 with breast cancer risk among women of European ancestry in the original GWAS, all stages combined (), and replication within the Breast Cancer Association Consortium (BCAC). Ca, no. cases; Co, no. controls; MAF, minor allele frequency. Study abbreviations as in . * The discovery set (see Results) comprises data from 2 BCAC studies that had contributed data to the GWAS analysis [BBCS contributed data on 1,711 (out of the 1,978 subjects examined here) to stages 1 and 2 of the GWAS; UKBGS contributed data on 4,621 (out of the 4,661 subjects examined here) to stage 3 of the GWAS].